[HTML][HTML] Pharmacotherapy for neuromyelitis optica spectrum disorders: current management and future options
N Collongues, E Ayme-Dietrich, L Monassier… - Drugs, 2019 - Springer
Neuromyelitis optica (NMO) is an inflammatory and demyelinating disease of the central
nervous system. Although the prevalence of NMO is low, the rapid and severe impairment …
nervous system. Although the prevalence of NMO is low, the rapid and severe impairment …
[PDF][PDF] Pharmacotherapy for Neuromyelitis Optica Spectrum Disorders: Current Management and Future Options
N Collongues, E Ayme‑Dietrich, L Monassier… - Drugs, 2019 - academia.edu
Neuromyelitis optica (NMO) is an inflammatory and demyelinating disease of the central
nervous system. Although the prevalence of NMO is low, the rapid and severe impairment …
nervous system. Although the prevalence of NMO is low, the rapid and severe impairment …
Pharmacotherapy for Neuromyelitis Optica Spectrum Disorders: Current Management and Future Options
N Collongues, E Ayme-Dietrich, L Monassier… - …, 2019 - pubmed.ncbi.nlm.nih.gov
Neuromyelitis optica (NMO) is an inflammatory and demyelinating disease of the central
nervous system. Although the prevalence of NMO is low, the rapid and severe impairment …
nervous system. Although the prevalence of NMO is low, the rapid and severe impairment …
Pharmacotherapy for Neuromyelitis Optica Spectrum Disorders: Current Management and Future Options.
N Collongues, E Ayme-Dietrich, L Monassier… - Drugs, 2019 - search.ebscohost.com
Neuromyelitis optica (NMO) is an inflammatory and demyelinating disease of the central
nervous system. Although the prevalence of NMO is low, the rapid and severe impairment …
nervous system. Although the prevalence of NMO is low, the rapid and severe impairment …
[引用][C] Pharmacotherapy for Neuromyelitis Optica Spectrum Disorders: Current Management and Future Options
N Collongues, E Ayme-Dietrich, L Monassier… - Drugs, 2019 - hal.science
Pharmacotherapy for Neuromyelitis Optica Spectrum Disorders: Current Management and
Future Options - Archive ouverte HAL Accéder directement au contenu Documentation FR …
Future Options - Archive ouverte HAL Accéder directement au contenu Documentation FR …
[引用][C] Pharmacotherapy for Neuromyelitis Optica Spectrum Disorders: Current Management and Future Options
N Collongues, E Ayme-Dietrich, L Monassier… - Drugs, 2019 - cir.nii.ac.jp
Pharmacotherapy for Neuromyelitis Optica Spectrum Disorders: Current Management and
Future Options | CiNii Research CiNii 国立情報学研究所 学術情報ナビゲータ[サイニィ] 詳細へ移動 …
Future Options | CiNii Research CiNii 国立情報学研究所 学術情報ナビゲータ[サイニィ] 詳細へ移動 …
Pharmacotherapy for Neuromyelitis Optica Spectrum Disorders: Current Management and Future Options.
N Collongues, E Ayme-Dietrich, L Monassier… - Drugs, 2019 - europepmc.org
Neuromyelitis optica (NMO) is an inflammatory and demyelinating disease of the central
nervous system. Although the prevalence of NMO is low, the rapid and severe impairment …
nervous system. Although the prevalence of NMO is low, the rapid and severe impairment …
Pharmacotherapy for Neuromyelitis Optica Spectrum Disorders: Current Management and Future Options
N Collongues, E Ayme-Dietrich, L Monassier… - Drugs, 2019 - search.proquest.com
Neuromyelitis optica (NMO) is an inflammatory and demyelinating disease of the central
nervous system. Although the prevalence of NMO is low, the rapid and severe impairment …
nervous system. Although the prevalence of NMO is low, the rapid and severe impairment …